Chemoinformaics analysis of 2,4-Dihydroxychalcone
| Molecular Weight | 240.258 | nRot | 3 |
| Heavy Atom Molecular Weight | 228.162 | nRig | 14 |
| Exact Molecular Weight | 240.079 | nRing | 2 |
| Solubility: LogS | -5.808 | nHRing | 0 |
| Solubility: LogP | 5.292 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 30 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 18 | No. of Aromatic Carbocycles | 2 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 12 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 12 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 12 |
| nHA | 3 | APOL | 35.4575 |
| nHD | 2 | BPOL | 12.9065 |
| QED | 0.669 |
| Synth | 3.012 |
| Natural Product Likeliness | 2.039 |
| NR-PPAR-gamma | 0.558 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.995 |
| Pgp-sub | 0.008 |
| HIA | 0.006 |
| CACO-2 | -4.713 |
| MDCK | 0.0000225 |
| BBB | 0.02 |
| PPB | 0.956651 |
| VDSS | 0.949 |
| FU | 0.0590651 |
| CYP1A2-inh | 0.964 |
| CYP1A2-sub | 0.461 |
| CYP2c19-inh | 0.958 |
| CYP2c19-sub | 0.17 |
| CYP2c9-inh | 0.833 |
| CYP2c9-sub | 0.924 |
| CYP2d6-inh | 0.89 |
| CYP2d6-sub | 0.833 |
| CYP3a4-inh | 0.695 |
| CYP3a4-sub | 0.19 |
| CL | 1.513 |
| T12 | 0.14 |
| hERG | 0.019 |
| Ames | 0.008 |
| ROA | 0.127 |
| SkinSen | 0.686 |
| Carcinogencity | 0.242 |
| EI | 0.907 |
| Respiratory | 0.395 |
| NR-Aromatase | 0.671 |
| Antiviral | No |
| Prediction | 0.778371 |